Medtronic is recalling more than 700 OmniaSecure defibrillation leads, urging customers to quarantine and return them. The FDA has ruled this is a Class II recall. No adverse events have been reported.

Certain Sapien M3 TMVR delivery systems have been linked to a risk of malfunctioning in a way that puts patients at risk. The devices included in this early alert should be returned to the manufacturer. 

This Class II recall was initiated due to a risk of clinicians encountering issues when deploying the Trilogy Transcatheter Heart Valve System. 

Medtronic identified an issue with its CareLink SmartSync device manager providing inaccurate longevity estimates for certain leadless pacemakers. Customers can download a software update to resolve the issue going forward.

The product at the heart of this recall is a dietary supplement taken to boost energy and performance when exercising. The FDA previously warned the public not to take it due to the potential side effects. 

Certain lots of argatroban, a blood thinner often used as an alternative to heparin during PCI, have been recalled due to the presence of particulate matter. The affected products should not be used to treat any patients due to an increased risk of adverse events.

This update comes just months after 11,000 bottles of the same drug were recalled due to a failed test. The FDA has classified this as a Class II recall. 

If a malfunction does occur, Stryker warned, it could impact the device's effectiveness. No adverse events have been reported at this time.